NASDAQ · GNPXHealthcarePharmaceuticals

Genprex financials

$2.85+1.42%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Gross margin————————
Operating income-$15.5M-$21.2M-$31.1M-$23.8M-$20.7M-$18.0M-$10.7M-$12.4M
Net income-$16.2M-$21.4M-$30.9M-$23.7M-$20.7M-$17.9M-$10.7M-$12.4M
Net margin————————
Diluted EPS$-382.80$-5871.58$-24816.00$-21780.00$-19360.00$-22440.00$-29040.00$-39600.00
EBITDA-$15.5M-$21.2M-$31.0M-$23.8M-$20.6M-$17.9M-$10.7M-$12.4M
Operating cash flow-$15.3M-$17.9M-$24.7M-$17.6M-$14.3M-$13.9M-$6.9M-$6.8M
Free cash flow-$15.3M-$17.9M-$24.7M-$17.6M-$14.3M-$16.2M-$7.8M-$6.9M
Diluted shares0.0M0.0M0.0M0.0M0.0M0.0M0.0M0.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$7.8M$1.6M$6.7M$21.0M$38.6M$27.3M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$10.2M$4.1M$10.7M$25.1M$42.9M$31.4M
Total liabilities$2.2M$2.5M$3.3M$2.8M$1.6M$450.7K
Shareholders' equity$8.0M$1.6M$7.4M$22.3M$41.3M$30.9M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology